The role of mNGS in the diagnosis of talaromycosis and case series.

The role of mNGS in the diagnosis of talaromycosis and case series.

Publication date: Feb 07, 2025

Talaromycosis is a rare fungal infection characterized by non-specific clinical features, often resulting in misdiagnosis. This study aimed to analyze four classic cases of Talaromyces marneffei infection diagnosed using metagenomic next-generation sequencing (mNGS) to improve understanding of its diagnosis and treatment. This study retrospectively analyzed cases of T. marneffei identified through mNGS at Peking Union Medical College Hospital. Four confirmed cases of talaromycosis were selected based on clinical diagnoses, supplemented by a review of relevant literature. We reviewed and compared the clinical features, laboratory indicators, treatment regimens, and outcomes of these cases, which exhibited varied characteristics. Among the four patients, two were human immunodeficiency virus (HIV)-positive, and two were HIV-negative. All the participants presented with fever and varying respiratory symptoms, with distinct clinical characteristics aiding diagnosis. Three cases exhibited significant pulmonary infection lesions. Both HIV-positive patients showed T. marneffei bloodstream dissemination and suffered mixed infection with virus. Within them, one case was positive in blood culture, blood mNGS and sputum culture. Another case was positive in blood and bone marrow cultures, brain tissue culture and mNGS. They were both treated with voriconazole and improved. Both HIV-negative patients were T. marneffei positive for BALF mNGS, and only one of them was positive for BALF culture. One of them was mix infected by fungi, bacteria, Mycobacterium tuberculosis and virus, improved by voriconzole and followed by introconaole. The other case was cured by introconazole. Traditional diagnostic methods are limited by factors such as the long time and low sensitivity of fungal culture, the effect of prior antibiotic treatment, the invasiveness and complexities of tissue biopsies, and so on. Emerging technologies, particularly mNGS, offer advantages such as rapid processing, high accuracy, and comprehensive pathogen coverage, significantly reducing the risk of missed diagnoses and facilitating timely intervention.

Open Access PDF

Concepts Keywords
Fungi Diagnosis
Hiv mNGS
Misdiagnosis Talaromycosis marneffei
Talaromycosis
Timely

Semantics

Type Source Name
disease IDO role
disease MESH talaromycosis
disease MESH fungal infection
disease MESH misdiagnosis
disease IDO immunodeficiency
disease MESH infection
disease MESH mixed infection
disease IDO blood
drug DRUGBANK Voriconazole
disease IDO bacteria
disease IDO pathogen
disease MESH missed diagnoses
disease IDO intervention
pathway REACTOME Reproduction
disease MESH Infectious Diseases
drug DRUGBANK Coenzyme M
drug DRUGBANK (S)-Des-Me-Ampa
disease MESH invasive fungal infection
disease IDO infection prevalence
disease IDO quality
disease MESH pneumonia
disease IDO history
disease MESH HIV infection
pathway REACTOME HIV Infection
disease MESH acquired immunodeficiency syndrome
disease MESH leukopenia
drug DRUGBANK Sulfamethoxazole
disease MESH opportunistic infections
disease MESH anemia
disease MESH malignancy
disease MESH hemolytic anemia
disease IDO susceptibility
drug DRUGBANK Amphotericin B
drug DRUGBANK Itraconazole
drug DRUGBANK Meticillin
disease MESH otitis media
disease MESH aplasia
disease MESH viral load
drug DRUGBANK Erythropoietin
disease IDO symptom
disease MESH pancytopenia
disease MESH diffuse large B cell lymphoma
drug DRUGBANK Methotrexate
disease MESH residual tumor
drug DRUGBANK Methylergometrine
disease MESH organizing pneumonia
drug DRUGBANK Meropenem
drug DRUGBANK Methylprednisolone
disease MESH thrombosis
disease MESH pulmonary embolism
drug DRUGBANK Enoxaparin
disease IDO nucleic acid
drug DRUGBANK Creatinine
disease MESH drug interactions
drug DRUGBANK Ritonavir
drug DRUGBANK Ganciclovir
disease MESH necrosis
disease MESH allergy
drug DRUGBANK Trestolone
drug DRUGBANK Ceftazidime
disease MESH neutropenia
drug DRUGBANK Filgrastim
disease IDO replication
disease MESH COVID 19
disease IDO process
disease MESH clinical course
disease MESH weight loss
disease MESH splenomegaly
disease MESH septicemia
disease MESH brain abscess
drug DRUGBANK Methyprylon
disease IDO immunosuppression
disease IDO host
disease MESH latent infection
disease MESH thrombocytopenia
disease MESH hypoalbuminemia
disease MESH lymphoma
drug DRUGBANK Deoxycholic Acid
disease MESH Rare Diseases
disease MESH Cardiovascular Disease
disease IDO virulence
disease MESH lifestyle
disease IDO assay
drug DRUGBANK Guanosine
disease MESH Central Nervous System infection
disease MESH visceral leishmaniasis
disease MESH histoplasmosis
disease MESH endophthalmitis
disease MESH syndrome
disease MESH carditis
disease MESH Cryptococcosis
drug DRUGBANK Carboxyamidotriazole

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *